-

Bristol Myers Squibb to Hold Investor Event on November 16

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will hold an Investor Event in New York City on Tuesday, November 16, 2021 at 9:30 a.m. ET. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, will be joined by members of the company’s leadership team to discuss the Company’s strategy, pipeline and business opportunities.

The event will also be simultaneously webcast at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Hold Investor Event on November 16
Release Versions

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Evolution of Research & Development Organization

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Evolution of Research & Development Organization...

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos......

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2026...
Back to Newsroom